Mechanisms of methicillin resistance in staphylococci

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
O G Brakstad, J A Maeland

Abstract

The continuously high prevalence of methicillin-resistant staphylococci (MRS) throughout the world is a constant threat to public health, owing to the multiresistant characteristics of these bacteria. Methicillin resistance is phenotypically associated with the presence of the penicillin-binding protein 2a (PBP2a) not present in susceptible staphylococci. This protein has a low binding affinity for beta-lactam antibiotics. It is a transpeptidase which may take over cell wall synthesis during antibiotic treatment when normally occurring PBPs are inactivated by ligating beta-lactams. PBP2a is encoded by the mecA gene, which is located in mec, a foreign DNA region. Expression of PBP2a is regulated by proteins encoded by the plasmid-borne blaR1-bla1 inducer-repressor system and the corresponding genomic mecRl-mecl system. The blaRl-blal products are important both for the regulation of beta-lactamase and for mecA expression. Methicillin resistance is influenced by a number of additional factors, e.g. the products of the chromosomal fem genes which are important in the synthesis of normal peptidoglycan precursor molecules. Inactivation of fem-genes results in structurally deficient precursors which are not accepted as cell wall buil...Continue Reading

References

Mar 1, 1992·Antimicrobial Agents and Chemotherapy·J E GustafsonB J Wilkinson
Jan 1, 1992·Antimicrobial Agents and Chemotherapy·C RyffelB Berger-Bächi
Apr 1, 1992·Acta Paediatrica Japonica; Overseas Edition·K FujitaM Kaeriyama
Aug 1, 1991·Antimicrobial Agents and Chemotherapy·D T DubinP R Stewart
Jan 1, 1990·Molecular Biology Reports·J A SteitzB Sollner-Webb
Dec 1, 1991·Antimicrobial Agents and Chemotherapy·G L Archer, J Scott
Aug 1, 1991·Journal of Medical Microbiology·E E Udo, W B Grubb
Oct 1, 1991·Journal of Clinical Microbiology·K MurakamiS Watanabe
Jun 1, 1991·Journal of Clinical Pathology·C ClaytonS Tabaqchali
Jan 1, 1990·Society for Applied Bacteriology Symposium Series·B Cookson, I Phillips
Sep 1, 1990·Antimicrobial Agents and Chemotherapy·G L Archer, E Pennell
May 1, 1990·Journal of Molecular and Cellular Cardiology·A P TimermanA J Merola
Apr 1, 1988·The Journal of Antimicrobial Chemotherapy·R A SkurrayJ W May
Nov 1, 1988·Journal of General Microbiology·M T GillespieR A Skurray
Apr 1, 1988·Clinical Microbiology Reviews·H F Chambers
Jan 1, 1986·Antimicrobial Agents and Chemotherapy·B J Hartman, A Tomasz
Feb 1, 1969·Journal of Bacteriology·D J Tipper
Feb 1, 1984·Journal of Medical Microbiology·B R LyonR A Skurray
Jul 1, 1982·Antimicrobial Agents and Chemotherapy·N H GeorgopapadakouD P Bonner
Sep 1, 1995·Journal of Clinical Microbiology·L A TeixeiraA Tomasz
Jul 1, 1995·Journal of Clinical Microbiology·W J Van WamelC M Vandenbroucke-Grauls

❮ Previous
Next ❯

Citations

Dec 26, 2001·Diagnostic Microbiology and Infectious Disease·P LemK Ramotar
Apr 4, 2002·Diagnostic Microbiology and Infectious Disease·Rosana Barreto Rocha FerreiraKátia Regina Netto dos Santos
May 15, 2002·Diagnostic Microbiology and Infectious Disease·Wendi WoodsBaldwin Toye
Apr 1, 2000·Diagnostic Microbiology and Infectious Disease·A K JafriG L Woods
Apr 15, 2000·Diagnostic Microbiology and Infectious Disease·S S WongK Y Yuen
Jan 28, 2003·Drug Discovery Today·Peter W TaylorJ Paul Luzio
Sep 16, 1998·Current Opinion in Chemical Biology·M B Schmid
Feb 18, 2003·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Isaac Ginsburg
Jun 27, 2000·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·S P YazdankhahH Oppegaard
Nov 9, 2012·Molecular Oral Microbiology·D OsbourneH M Fletcher
Oct 22, 2011·International Journal of Molecular Sciences·Seong-Cheol ParkKyung-Soo Hahm
Dec 21, 2005·Biomaterials·Davide CampocciaCarla Renata Arciola
Jun 22, 2000·The Journal of Hospital Infection·E M SzewczykM Rózalska
Feb 8, 2000·The Journal of Antimicrobial Chemotherapy·R A Lewis, K G Dyke
Jan 1, 2013·Polish Journal of Veterinary Sciences·M BochniarzM Szczubial
Apr 10, 2010·Microbiology·Devon O OsbourneHansel M Fletcher
Jul 16, 2017·Scientific Reports·Do-Won JeongJong-Hoon Lee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.